DK1461360T3 - Conjugates comprising an antibody specific for ED-8 domains of fibronectin and their use for the detection and treatment of tumors - Google Patents

Conjugates comprising an antibody specific for ED-8 domains of fibronectin and their use for the detection and treatment of tumors

Info

Publication number
DK1461360T3
DK1461360T3 DK03726977.6T DK03726977T DK1461360T3 DK 1461360 T3 DK1461360 T3 DK 1461360T3 DK 03726977 T DK03726977 T DK 03726977T DK 1461360 T3 DK1461360 T3 DK 1461360T3
Authority
DK
Denmark
Prior art keywords
fibronectin
treatment
conjugates
tumors
domains
Prior art date
Application number
DK03726977.6T
Other languages
Danish (da)
Inventor
Dietmar Berndorff
Ludger Dinkelborg
Dieter Moosmayer
Giovanni Neri
Christoph-Stephan Hilger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Priority claimed from PCT/EP2003/000009 external-priority patent/WO2003055917A2/en
Application granted granted Critical
Publication of DK1461360T3 publication Critical patent/DK1461360T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to methods for diagnosis and treatment of tumours, using peptides for binding radionuclides. The peptides comprise an antigen- binding site for the extra domain B (ED-B) of fibronectin.
DK03726977.6T 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for ED-8 domains of fibronectin and their use for the detection and treatment of tumors DK1461360T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Publications (1)

Publication Number Publication Date
DK1461360T3 true DK1461360T3 (en) 2010-11-15

Family

ID=35976951

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726977.6T DK1461360T3 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for ED-8 domains of fibronectin and their use for the detection and treatment of tumors

Country Status (8)

Country Link
KR (2) KR20100077052A (en)
AT (1) ATE478095T1 (en)
DE (1) DE60333820D1 (en)
DK (1) DK1461360T3 (en)
ES (1) ES2346750T3 (en)
PT (1) PT1461360E (en)
SI (1) SI1461360T1 (en)
ZA (1) ZA200406162B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070526A1 (en) 2017-10-02 2019-04-11 Battelle Energy Alliance, Llc Methods and systems for the electrochemical reduction of carbon dioxide using switchable polarity materials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis

Also Published As

Publication number Publication date
KR100998803B1 (en) 2010-12-06
KR20100077052A (en) 2010-07-06
ZA200406162B (en) 2005-09-27
DE60333820D1 (en) 2010-09-30
ES2346750T3 (en) 2010-10-20
ATE478095T1 (en) 2010-09-15
PT1461360E (en) 2010-11-23
KR20040073540A (en) 2004-08-19
SI1461360T1 (en) 2010-12-31

Similar Documents

Publication Publication Date Title
MXPA04006517A (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours.
DK1472541T3 (en) Imaging agents and methods for imaging NAALADase and PSMA
ATE505489T1 (en) TGF-BETA-1 SPECIFIC ANTIBODIES
DK2135881T3 (en) Antibodies that bind to the tumor-associated antigen TAT10772 for the diagnosis and treatment of tumor
DK1553975T3 (en) Optimized Fc variants and methods for their generation.
NO2017019I1 (en) Diarylhydantoin compound, pharmaceutical composition and use thereof
DK1773885T3 (en) Humanized anti-c-met antagonists
EA201100923A1 (en) HUMAN ANTIBODIES AGAINST THE TISSUE FACTOR
DK1287140T3 (en) Antibody molecules having specificity for human tumor necrosis factor alpha and its use
DK1660513T5 (en) CA6 antigen-specific, cytotoxic conjugate and methods for its use
CY1116037T1 (en) CATALOG OF ACTIVITIES A AND USE OF THESE
EA200702053A1 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
NO20073797L (en) Human monoclonal antibodies against prostate specific membrane antigen (PSMA)
EA200901313A1 (en) BLUTON TYROSINKINASE INHIBITORS
MA29595B1 (en) HUMANIZED ANTI-CD40 ANTIBODIES AND METHODS OF USE
CY1111860T1 (en) ANTIBODIES AGAINST TOY CLOSTRIDIUM DIFFICILE TOXINS AND USE OF THESE
WO2003034903A3 (en) Psma antibodies and protein multimers
NO20083053L (en) Human monoclonal antibodies to O8E
DK1406656T3 (en) Methods for administering anti-TNF alpha antibodies
NO20071436L (en) Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
NO20054351L (en) Monoclonal antibody and hybridoma producing this
DK1904102T3 (en) ANTI-CCR7 receptor antibodies for the treatment of cancer
ATE517920T1 (en) HUMANIZED ANTIBODIES AGAINST INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
DK1641828T3 (en) Anti-HGF-R antibodies and their use